<DOC>
	<DOCNO>NCT02300389</DOCNO>
	<brief_summary>The main purpose study compare effectiveness Hypofractionated IMRT boost Radiotherapy Conventional IMRT boost Radiotherapy high-risk prostate cancer patient combine Androgen Deprivation Therapy .</brief_summary>
	<brief_title>Randomized , Multi-center Clinical Trial Comparing Hypofractionated Radiotherapy Boost Conventionally Fractionated Combined With Androgen Deprivation Therapy High Risk Group Prostate Cancer Patients</brief_title>
	<detailed_description>Additional objective study high-risk ( non-metastatic ) prostate cancer patient follow : 1 . Analysis number circulate tumor cell peripheral blood prognostic/predictive factor survival . 2 . Analysis miRNA expression level ( 100 , 141 143 ) peripheral blood prognostic predictive factor . 3 . Evaluation usefulness expression select protein ( PTEN , SMAD4 , Cyclin D1 , SPP1 ) prognostic predictive factor . 4 . Evaluation usefulness expression level antigen-specific T cell , B-and NK cell prognostic factor . 5 . Evaluation usefulness fiducial marker localize prostate gland position irradiation select control image method ( 2DkV , CBCT , MVCT ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>men 40 75 year old confirm prostate adenocarcinoma , prostate biopsy perform &lt; 180 day date randomization , complete assessment tumor differentiation accord Gleason grading allow perform stratification ; Gleason score â‰¤ 7 versus Gleason score &gt; 8 , general condition accord classification Eastern Cooperative Oncology Group ( ECOG ) 0 1 ) , ( Appendix 1 ) , Androgen Deprivation Therapy : prior Radiotherapy ( RT ) ( minimum 3 month start RT ) , concurrently RT RT followup ( 24 month ) , high risk Prostate Cancer progression define presence least one follow factor : cT3 , Gleason &gt; 7 , PSA &gt; 20 ng / ml presence least two cT2c , Gleason 7 , PSA range 10.1 ng / ml 19.9 ng / ml , cT define AJCC stag 7 edition , ( Appendix 2 ) , PSA identify least 10 day biopsy , patient receive fiansteryd 30 day cessation therapy , regional distant metastasis confirm bone scintigraphy , chest radiograph , compute tomography/magnetic resonance image pelvis , sign inform consent participate medical experiment ( radiotherapy + biological material sample ) ( Annex 3 ) , morphological biochemical parameter within normal limit . presence active cancer except skin cancer precede period 5 year prior randomization , Early surgery ( radical prostatectomy ) pelvic RT , earlier hormonal therapy advocate study , comorbidities may significantly affect expectancy life patient meet criterion inclusion .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>high risk prostate cancer radiotherapy hypofractionation</keyword>
</DOC>